Finnish expertise at HLTH USA 2025

Buddy Healthcare

Buddy Healthcare’s Care Coordination Platform streamlines perioperative and specialty care pathways by automating communication, digitizing forms and questionnaires (e.g., pre-operative assessments and patient-reported outcomes), and providing real-time data visualization. This helps care teams prepare patients more efficiently before treatment and ensures smoother recovery and follow-up. 

Designed in close collaboration with leading healthcare providers, the platform supports smarter, data-driven workflows by enabling providers to categorize and prioritize patients based on submitted questionnaires. 

This reduces administrative burden and allows staff to focus more on direct patient care. Hospitals and clinics using Buddy Healthcare’s platform have achieved measurable improvements such as reducing phone calls by up to 98%, lowering cancellation rates by 30%, and significantly cutting overall care delivery costs.

Contact:
Jussi Määttä
CEO
+358 40 552 2151
jussi (at) buddyhealthcare.com

BusinessOulu / OuluHealth

OuluHealth is a dynamic and versatile ecosystem from Oulu in northern Finland. The ecosystem brings together stakeholders from the health sector and facilitates cooperation between them to improve future health and social care services.

The ecosystem provides versatile support for research, co-creation of health solutions and entrepreneurial success. Whether you would like to test your solution in innovation testing and development environments, aim to attract more visibility to your innovation, look for contacts or consider new business opportunities, we are here to help you reach your goals.

Clever Health Network

CleverHealth Network is a health technology ecosystem established in 2017, where companies and healthcare professionals co-develop better care for Finnish citizens while creating successful health technology export products. The network’s innovations are built on the extensive, high-quality health data of HUS Helsinki University Hospital and the top-level clinical expertise of its professionals.

Coordinated by HUS and funded by Business Finland, the ecosystem’s partners include Alinesoft, AstraZeneca, Avaintec, BCB Medical, BC Platforms, CGI, Fujitsu, GE Healthcare, Hewlett Packard Enterprise, Innofactor, Medlyse, Medtronic, Microsoft, Novartis, Productivity Leap, Roche, Siemens Healthineers, Telia, Tietoevry, and Varian.

The vision of CleverHealth Network is to be an internationally recognized ecosystem that leverages and refines health and wellbeing data. We aim to be a pioneer in transforming healthcare and to create multiple world-class, data-driven solutions every year.

Health ahead. Together.

Contact:
Tiina Puurtinen
Development manager
tiina.puurtinen (at) hus.fi

CurifyLabs

CurifyLabs Compounding System Solution (CSS) is a breakthrough platform that brings the future of personalized medicine into everyday pharmacy practice. Traditionally, compounding medicines—customizing drugs for patients—has been slow, manual, and error-prone. CSS changes that with a fully digital and automated solution.

With CSS, pharmacies can create personalized medicines tailored in dose, taste, shape, and release profile, covering everything from children’s chewables to polypills that combine multiple therapies. It supports nearly all therapeutic areas while keeping processes safe, consistent, and transparent.

The benefits are profound: four times faster production, fewer errors, longer shelf life, and safer working conditions for staff. Already tested by pharmacists and adopted in hospitals across 14+ countries, CSS ensures compliance with U.S. regulations while preparing pharmacies for the next era of healthcare. By standardizing and automating compounding, CurifyLabs is future-proofing how personalized medicines are made—scalable, reliable, and ready for global impact.

Contact:
Charlotta Topelius
CEO
+358 400 188 781 
charlotta (at) curifylabs.com

EFSim

EFSim, developed by Finnish health technology company Peili Vision, is a certified Class IIa medical device transforming how ADHD pathways are managed worldwide. EFSim is a web-based, gamified tool that assesses executive functions and attention in children through everyday tasks in a realistic, simulated home environment. Guided by an engaging avatar, children complete activities that generate precise, reliable insights into attention, memory, planning, and impulse control.

Validated through clinical studies, EFSim has demonstrated a strong correlation with established ADHD measures and proven reliability. Its automatically generated reports support clinicians, families, and educators with clear, actionable insights, enabling earlier identification, timely interventions, and more personalized care.

By combining scientific evidence with intuitive design, EFSim offers a scalable and accessible digital pathway, delivering significant cost savings and enhancing ADHD assessments and titration with actionable, objective insights.

Contact:
Kimmo Sainio
Head of Sales 
+358 40 632 5279
kimmo.sainio (at) efsimtest.com

Kiwecare

Kiwecare (Smart PD Solutions Ltd.) is a Finnish med-tech company dedicated to transforming kidney care through innovative, non-invasive monitoring solutions for peritoneal dialysis (PD) patients. Our patented technology enables real-time detection of infections and continuous monitoring of dialysis quality directly from the drain line, without interfering with the treatment process. This addresses a critical global need: peritonitis and treatment complications remain leading causes for hospitalizations, high costs, and patients dropping out of home dialysis.

By combining advanced biosensors, AI-driven analytics, and seamless cloud connectivity, Kiwecare empowers patients with safer home treatments and gives healthcare providers actionable insights to intervene early, improving outcomes while reducing healthcare costs. With over 850 million people living with chronic kidney disease worldwide, and dialysis costs surpassing those of cancer and diabetes combined, our solution offers scalable impact to healthcare systems globally.

Contact:
Juha Remahl
CEO
+358 50 552 2161
juha.remahl (at) kiwecare.com

Koite Health

Koite Health Ltd., established in 2018, develops innovative photothermal and photodynamic therapy (PDT) solutions addressing the global challenge of antimicrobial resistance by reducing the need for antibiotics.

Our first commercial product, Lumoral®, is a CE-marked medical device, also approved in the UK and Switzerland, designed to prevent and treat tooth decay and gum disease. Supported by strong clinical evidence, patent protection, and a growing customer base exceeding one million treatments, Lumoral® together with Lumorinse® provides robust recurring revenue streams.

Building on this foundation, we are expanding into high-impact therapeutic areas, including Oncolum® for cancer treatment–associated oral mucositis and wound-healing applications against MRSA and other resistant infections.

With ISO 9001 and ISO 13485 certified operations, a scalable business model, and strategic partnerships with leading medical and pharmaceutical companies, Koite is positioned as a global leader in antibacterial and biofilm management. Having given over 1,000,000 treatments, we are shaping a future where safe, effective, and accessible PDT-based treatments redefine standards in oral health and beyond.

Contact:
Sakari Nikinmaa
Co-Founder
+358 40 822 2034
sakari (at) koitehealth.com

Moncyte Health

MONCYTE Health delivers the first cellular lipid-fingerprint, a holistic solution that quantifies residual CVD risk and links it to a precision treatment recommendation. We integrate cellular diagnostics with robotics, high-resolution imaging, advanced software, and AI to systematically—and at scale—measure the cellular mechanisms that drive inflammation, plaque progression, and treatment response.

Unlike traditional biomarker tests that estimate risk but rarely guide next steps, MONCYTE provides actionable, disease-relevant insight and an optimal lipid-lowering strategy for each patient. In clinical practice, physicians gain a deep view of the cellular drivers of residual risk and a clear, personalized plan and removing trial-and-error.

For pharmaceutical partners, individual modules can be deployed as novel clinical readouts to show how a drug shifts cellular drivers, identify the right patient cohorts, and generate evidence that supports market access.

Contact:
Tamara Alagirova
CEO & Founder
+358 40 5779945
ta (at) moncytehealth.com

Nadmed

NADMED offers advanced diagnostic solutions for accurately measuring NADs, the bodily form of vitamin B3 and its derivatives, which are key biomarkers of cellular health, energy metabolism, and disease progression. Traditional methods for measuring NAD have been limited by low sensitivity, lengthy turnaround times, and complex workflows, creating a significant gap for researchers, clinicians, and pharmaceutical developers who need reliable, real-time metabolic insights. NADMED’s innovative technology and ready-to-use kits fill this gap by providing fast, reproducible, and accurate results across a range of applications (e.g., neuromuscular and neurodegenerative diseases, obesity, mitochondrial diseases), enabling researchers, laboratories, and healthcare providers to better understand disease mechanisms, monitor patient status, and assess treatment effects.

As global demand increases for tools supporting healthy aging, precision medicine, and advanced drug development, NADMED combines scientific accuracy with ease of use and scalability for advanced research, diagnostics, and pharmaceutical markets. Our technology accelerates discoveries, improves patient insights, and fosters a clearer understanding of how cellular metabolism influences health and disease, driving the future of metabolic diagnostics worldwide.

Contact:
Jari Närhi
CEO
+358 40 560 3165
jari.narhi (at) nadmed.com

Otos

Otos Health is a health technology company with presence in Finland and in the US. The company is capitalizing on the largest disruption in hearing care in 50 years, tackling a crisis affecting 1 in 5 people (1 in 4 by 2050)—80% of whom go undiagnosed. Current primary care assessments are slow and resource-intensive, leaving millions without timely intervention.

Our patent-pending OSystem™, designed for the primary care workflow, empowers non-clinical staff to run parallel, gold-standard tests 50% faster, increasing throughput 5x. With seamless EHR integration and by unlocking new reimbursement, we deliver a powerful 184% ROI for clinics (600%+ for networks), turning a cost center into a profit engine. We are targeting a $2.1B US opportunity within an $11.4B global market.

Born through collaboration with Aalto University and Helsinki University Hospital, Otos combines world-class clinical expertise with scalable technology to meet the global demand for accessible and efficient hearing healthcare. With a pipeline of leading US institutions, we are building the professional clinical layer to meet surging consumer demand, redefining hearing care by closing critical gaps in access, efficiency, and outcomes.

Contact:
Wycliffe Raduma
Co-founder & CEO
+358 50 351 7554
wycliffe (at) otos.health

Tanja Tervonen
Co-founder & COO
+358 400 240 800
tanja (at) otos.health

QuietOn

QuietOn earbuds are advanced active noise cancelling sleep devices designed to help users achieve deeper, uninterrupted rest and improve overall wellbeing. They address the growing global need for effective solutions to sleep disturbances caused by snoring, urban noise, and travel environments. Unlike traditional earplugs, QuietOn uses sophisticated ANC technology to cancel low-frequency sounds while maintaining a compact, ergonomic design that fits comfortably in the ear, ideal also for side sleepers.

One of QuietOn’s key strengths is its effortless usability: no Bluetooth, apps, or pairing is required. Simply place the earbuds in your ears and they begin working instantly. This simplicity makes them perfect for anyone seeking peace and quiet without technical hassle. The earbuds combine Nordic high-performance engineering with minimalist design, offering a sustainable and effective solution in the wellness tech space. Whether at home, in hotels, or on the move, QuietOn helps users reclaim restful sleep and quiet moments—easily and reliably.

Contact:
Katja Siberg
CEO
+358 400 995 796
katja.siberg (at) soundlesstech.com

SolidIO

Solid IO develops next-generation diagnostics that bring clarity and impact to cancer treatment. Our platform replicates each patient’s tumor–immune response outside the body, generating data that show whether a patient is likely to benefit from immuno-oncology (IO) therapy. Today, most IO drugs do not reach the patients who would truly benefit, creating challenges for healthcare systems, slowing drug development, and causing inequality for patients. By delivering human-relevant insight early, Solid IO supports pharma and biotech in research related to developing and validating new drugs, and in the future will help doctors make treatment decisions with confidence. Our science-based approach combines reliability, scalability, and global applicability, ensuring that more patients worldwide will gain access to therapies that work.

Contact:
Noora Hujala
CEO and co-founder
+358 50 3414801
noora.hujala (at) solid-io.com

Invest in Finland – at your service

Invest in Finland, as Finland's official investment promotion agency, provides confidential, personalized support and services for international companies exploring business opportunities in Finland. Whether you’re scaling your digital health solution, setting up R&D, or entering the EU market, our experts will connect you with the right people, data, and partners – all free of charge.

The Invest in Finland team is here to support your journey from start to Finnish.

Business Finland

Health 360 Finland is Business Finland’s strategic program driving international growth and innovation in Finland’s health sector. We bring together Finnish companies, research institutions, and public sector partners to co-develop scalable solutions for global healthcare challenges – from digital therapeutics and AI-driven diagnostics to preventive care, personalized medicine, and beyond.

The program supports collaboration between Finnish and international players across the entire health ecosystem. Through Health 360 Finland, we accelerate access to high-quality innovations, promote partnerships, and enable joint development and piloting with some of the most digitally advanced healthcare providers in the world.